CompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing… (NCT06770426) | Clinical Trial Compass
Not Yet RecruitingPhase 3
CompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN
South Korea40 participantsStarted 2025-02
Plain-language summary
Progressing stroke is associated poor functional outcome and neurological deficit.
Currently, no treatment for progressing stroke is recommended on the guideline.
Carbogen is a mixture of 5% CO2 with 95% O2. Carbogen is safe and it is used for the treatment of sudden sensory neural hearing loss or ocular ischemia.
CO2 dilate cerebral arteriole and concentration of CO2 is correlated with cerebral blood flow.
Increased cerebral blood flow following dilation of cerebral arteriole by CO2 might halt and revert progressing stroke.
Induced hypertension is alternative treatment of progressing stroke. Increasing blood pressure also induce cerebral blood flow. Phenylephrine is an α1 agonist, phenylephrine act on peripheral artery and little effect on cerebral artery or heart. Several studies reported that the effectiveness of phenylephrine on progressing stroke.
Therefore, this study will compare the effectiveness of carbogen + phenyleprhine versus phenlyephrine in progressing stroke patients.
Who can participate
Age range
20 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥20 years
* Anterior circulation progressing stroke
* Neurological worsening either 1 point in NIHSS score or MRC grade
Exclusion Criteria:
* Age under 20 years.
* Patients with cerebral infarction who are at risk of cerebral edema as determined by the investigator.
* Patients with Moyamoya disease.
* Patients with severe cerebrovascular reactivity (CVR) impairment due to cerebral vascular stenosis, making study participation challenging as determined by the investigator.
* Patients unable to undergo CO2 treatment (e.g., panic disorder, anxiety disorders, or other psychiatric conditions).
* Patients with hypersensitivity to phenylephrine.
* Patients with persistent bradycardia (heart rate \< 50 bpm).
* Patients with a history of hemorrhagic stroke or at risk of cerebral hemorrhage.
* Patients with a pre-stroke modified Rankin Scale (mRS) score ≥ 2, indicating impaired functional independence.
* Patients ineligible for phenylephrine treatment due to any of the following:
Myocardial infarction or unstable angina within the past 3 months. Cardiac ejection fraction \< 25%. Ventricular arrhythmia. Systolic blood pressure \> 200 mmHg. Serum creatinine \> 2 mg/dL. Pregnancy.
* Use of monoamine oxidase (MAO) inhibitors.
* Patients who do not consent to participate in the study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.